Table 2.
With Adenomyosis n = 150 | Without Adenomyosis n = 1434 | χ2 | P | |
---|---|---|---|---|
Histology | ||||
Endometrioid cancer | 140 (93.33%) | 1294 (90.23%) | ||
Non-endometrioid cancer | 10 (6.67%) | 140 (9.76%) | 1.519 | 0.218 |
Stage | ||||
I-II | 139 (92.67%) | 1227 (85.56%) | ||
III-IV | 11 (7.33%) | 207 (14.44%) | 5.771 | 0.016 |
Grade | ||||
1-2 | 137 (91.33%) | 1212 (84.52%) | ||
3 | 13 (8.67%) | 222 (15.48%) | 4.991 | 0.025 |
Myometrial invasion | ||||
< 1/2 | 135 (90%) | 1115 (77.75%) | ||
≥ 1/2 | 15 (10%) | 319 (22.25%) | 12.237 | < 0.001 |
LVSI | ||||
No | 144 (96%) | 1341 (93.51%) | ||
Yes | 6 (4%) | 93 (6.49%) | 1.513 | 0.219 |
Cervical invasion | ||||
No | 124 (82.67%) | 1105 (77.06%) | ||
Yes | 26 (17.33%) | 329 (22.94%) | 2.457 | 0.117 |
Adnexa invasion | ||||
No | 144 (96.64%) | 1330 (93.46%) | ||
Yes | 5 (3.36%) | 93 (6.54%) | 2.333 | 0.127 |
Pelvic LN metastasis | ||||
No | 131 (97.04%) | 1176 (92.09%) | ||
Yes | 4 (2.96%) | 101 (7.91%) | 4.339 | 0.037 |
Aortic LN metastasis | ||||
No | 96 (100%) | 767 (95.64%) | ||
Yes | 0 | 35 (4.36%) | - | - |
LVSI: Lymphovascular space invasion.